← Leaderboards
Amit Singal
Ut Southwestern Medical Center
$17,388,983
Attributed
$28,473,240
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2017–25$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,986,540 · 13
By mechanism
R01$14,163,359 · 5
U01$13,927,464 · 4
P50$2,737,308 · 2
P30$158,409 · 2
Top collaborators
- Yujin Hoshida11 shared
- Fasiha Kanwal9 shared
- Adam Yopp7 shared
- Richard R Drake5 shared
- Anand S Mehta5 shared
- Jorge A Marrero4 shared
- Neehar Dilip Parikh4 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Konstantin Doubrovinski$2,640,199
- Michael Buszczak$10,005,304
- Adam Yopp$5,283,383
- Elisabeth D Martinez$4,685,595
- Samir Gupta$7,838,582
Others in their field
Other Emerging Leaders on “Primary Carcinoma Of The Liver Cells”
- William H. Peranteau · Children'S Hosp Of Philadelphia$7,624,302
- Amaia Lujambio · Icahn School Of Medicine At Mount Sinai$5,368,450
- Valerian Nakaar · Carogen Corporation$4,718,929
- Cynthia A Moylan · Duke University$4,605,130
- Vera Hoffman · Reveal Pharma$4,535,285
- Yazhen Zhu · University Of California Los Angeles$4,488,782
Research focus
Primary Carcinoma Of The Liver CellsCirrhosisSerumTumorBiological MarkersMortalityCohortLiver DiseasesDetectionDiagnosisMalignant NeoplasmsEvaluationFundingEarly DiagnosisScreeningHigh RiskCancer EtiologyEtiologyCessation Of LifeBaseAlpha-FetoproteinsBloodAbdomenPublic Health
Grant awards (48)
UT Southwestern Liver Cancer SPORE$2,513,300
P50 · FY2025 · CA · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules$2,104,865
U01 · FY2025 · CA · contact PI
Clinical Validation Center for Hepatocellular Carcinoma$893,833
U01 · FY2025 · CA · contact PI
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes$867,274
R01 · FY2025 · CA
Core A - Administrative & Outreach$224,008
P50 · FY2025 · CA · contact PI
Clinical Validation Center for Hepatocellular Carcinoma$1,007,940
U01 · FY2024 · CA · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules$846,605
U01 · FY2024 · CA · contact PI
Epigallocatechin gallate for prevention of lethal cirrhosis complications$585,642
R01 · FY2024 · CA
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes$437,152
R01 · FY2024 · CA
Clinical Validation Center for Hepatocellular Carcinoma$1,041,376
U01 · FY2023 · CA · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules$907,163
U01 · FY2023 · CA · contact PI
Epigallocatechin gallate for prevention of lethal cirrhosis complications$684,526
R01 · FY2023 · CA
Glycopathology of HCC: identification of the source cells of serum fucosylation$603,318
U01 · FY2023 · CA
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes$596,725
R01 · FY2023 · CA
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis$249,951
R01 · FY2023 · CA · contact PI
Population Science and Cancer Control Program$52,803
P30 · FY2023 · CA · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$898,744
R01 · FY2022 · MD · contact PI
Clinical Validation Center for Hepatocellular Carcinoma$787,434
U01 · FY2022 · CA · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States$718,920
U01 · FY2022 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$603,318
U01 · FY2022 · CA
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes$545,848
R01 · FY2022 · CA
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis$399,134
R01 · FY2022 · CA · contact PI
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis$376,765
R01 · FY2022 · CA · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$93,598
R01 · FY2022 · MD · contact PI
Population Science and Cancer Control Program$52,803
P30 · FY2022 · CA · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$922,828
R01 · FY2021 · MD · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States$701,712
U01 · FY2021 · CA · contact PI
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis$599,410
R01 · FY2021 · CA · contact PI
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes$563,756
R01 · FY2021 · CA
Glycopathology of HCC: identification of the source cells of serum fucosylation$413,676
U01 · FY2021 · CA
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis$214,141
R01 · FY2021 · CA · contact PI
Population Science and Cancer Control Program$52,803
P30 · FY2021 · CA · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$799,053
R01 · FY2020 · MD · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States$692,985
U01 · FY2020 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$615,632
U01 · FY2020 · CA
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis$609,853
R01 · FY2020 · CA · contact PI
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis$486,994
R01 · FY2020 · CA · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$31,104
R01 · FY2020 · MD · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$699,053
R01 · FY2019 · MD · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States$682,917
U01 · FY2019 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$552,594
U01 · FY2019 · CA
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis$483,382
R01 · FY2019 · CA · contact PI
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis$297,396
R01 · FY2019 · CA · contact PI
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma$805,897
R01 · FY2018 · MD · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States$753,176
U01 · FY2018 · CA · contact PI
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis$662,072
R01 · FY2018 · CA · contact PI
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis$562,950
R01 · FY2018 · CA · contact PI
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis$690,111
R01 · FY2017 · CA · contact PI